Foveolar type dysplasia in Barrett esophagus

Modern Pathology

Volumn 23, Issue 6, 2010, Pages 834-843

  Brown, Ian S ^a   Whiteman, David C ^b   Lauwers, Gregory Y ^c  

^a SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Barrett esophagus; Foveolar dysplasia; Intestinal metaplasia

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; MUCIN 2; MUCIN 5AC; PROTEIN P53; TRANSCRIPTION FACTOR CDX2; VILLIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INVASION; CELL DIFFERENTIATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRECTOMY; ESOPHAGUS SURGERY; FEMALE; FOVEOLAR DYSPLASIA; GASTRECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOMA; AGED; BARRETT ESOPHAGUS; CELL DIFFERENTIATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; METAPLASIA; MICROFILAMENT PROTEINS; MIDDLE AGED; MUCIN 5AC; MUCIN-2; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953128254     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.59     Document Type: Article

References (47)

1. Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-868.
2. Devesa SS, Blot WJ, Fraumeni Jr JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
3. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;4:645-654.
4. Lord RV, Law MG, Ward RL, et al. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998;4:356-362.
5. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005; 128:1554-1566.
6. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295:476-480.
7. Skinner DB, Walther BC, Riddell RH, et al. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983;198:554-565.
8. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocar-cinoma arising in Barrett's esophagus. Am J Clin Pathol 1987;87:301-312.
9. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroen-terology 1996;110:614-621.
10. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 2009;40:65-74.
11. Clark GW, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-614.
12. Cameron AJ, Souto EO, Smyrk TC. Small adenocarci-nomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol 2002;97:1375-1380.
13. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarci-noma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-1546.
14. Nunobe S, Nakanishi Y, Taniguchi H, et al. Tw o distinct pathways of tumorigenesis of adenocarcino-mas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int 2007;57: 315-321.
15. Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroeso-phageal junction and gastric cardia? Dis Esophagus 2007;20:36-41.
16. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett's Esophagus. J Cancer Red Clin Oncol 1985;110:145-152.
17. Riddell RH, Odze RD. Definition of Barrett's Esophagus: Time for a Rethink\Is Intestinal Metaplasia Dead? Am J Gastroenterol 2009;104:2588-2594.
18. Steininger H, Pfofe DA, Müller H, et al. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005;201:573-577.
19. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004;17:1282-1288.
20. Phillips RW, Frierson Jr HF, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003;27:1442-1447.
21. Shi XY, Bhagwandeen B, Leong AS. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. Am J Clin Pathol 2008;129:571-577.
22. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009;104:816-824.
23. Hahn HP, Blount PL, Ayub K, et al. Intestinal Differentiation in Metaplastic, Nongoblet Columnar Epithelium in the Esophagus. Am J Surg Pathol 2009;33:1006-1015.
24. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-797.
25. Odze RD. Update on the diagnosis and treatment of Barrett esophagus and related neoplastic precursor lesions. Arch Pathol Lab Med 2008;132:1577-1585.
26. Yantiss RK, Odze RD. Neoplastic precursor lesions of the upper gastrointestinal tract. Diag Histopathol 2008;14:437-451.
27. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 2006;59:1029-1038.
28. Park do Y, Srivastava A, Kim GH, et al. Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol 2008;32:524-533.
29. Rucker-Schmidt RL, Sanchez CA, Blount PL, et al. Nonadenomatous dysplasia in Barrett Esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol 2009;33:886-893.
30. Yonezawa S, Nakamura A, Horinouchi M, et al. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepa-tobiliary Pancreat Surg 2002;9:328-341.
31. Ban S, Naitoh Y, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol 2006;30:1561-1569.
32. Katabi N, Klimstra DS. Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin Pathol 2008; 61:1303-1313.
33. Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008;57:173-180.
34. Hamilton SR, Aaltonen LA, (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. IARC Press: Lyon, 2000.
35. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32: 368-378.
36. Mahajan D, Bennett AE, Liu X, et al. Grading of gastric foveolar-type dysplasia in Barrett's esophagus. Mod Pathol 2010;23:1-11.
37. Takubo K, Aida J, Sawabe M, et al. The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endo-scopy. Best Pract Res Clin Gastroenterol 2008;22: 569-583.
38. Takubo K, Sasajima K, Yamashita K, et al. Double muscularis mucosae in Barrett's esophagus. Hum Pathol 1991;22:1158-1161.
39. Lewis JT, Wang KK, Abraham SC. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for Barrett esophagus: implications for staging of adenocarcinoma. Am J Surg Pathol 2008;32:566-571.
40. DeNardi FG, Riddell RH. The normal esophagus. Am J Surg Pathol 1991;15:296-309.
41. Asthana N, Mandich D, Ligato S. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus. Am J Surg Pathol 2008;32:1581-1585.
42. Kushima R, Vieth M, Mukaisho K, et al. Pyloric gland adenoma arising in Barrett's esophagus with mucin immunohistochemical and molecular cytogenetic evaluation. Virchows Arch 2005;446:537-541.
43. Leedham SJ, Preston SL, McDonald SA, et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008;57:1041-1048.
44. Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 2008;21:43-50.
45. Zhang HY, Spechler SJ, Souza RF. Esophageal adeno-carcinoma arising in Barrett esophagus. Cancer Lett 2009;275:170-177.
46. Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007;42: 1271-1274.
47. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006;55:442.